{"disease":{"id":"hypereosinophilic-syndrome","name":"hypereosinophilic syndrome"},"drugs":{"marketed":[{"drug_id":"gleevec","indication_name":"Idiopathic hypereosinophilic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"part-c-met097","indication_name":"Treatment of Hypereosinophilic Syndrome (HES)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"imatinib","indication_name":"Idiopathic hypereosinophilic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04538937","title":"Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Medical University Innsbruck","has_results":false},{"nct_id":"NCT06172751","title":"TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07444567","title":"Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":230,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04191304","title":"A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05334368","title":"Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":123,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02836496","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03306043","title":"A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00086658","title":"Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT00097370","title":"Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00044304","title":"Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00255346","title":"Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00091871","title":"A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06477653","title":"Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT01524536","title":"Steroid Treatment for Hypereosinophilic Syndrome","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04965636","title":"Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02101138","title":"Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03801434","title":"Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"William Shomali","has_results":false},{"nct_id":"NCT04498871","title":"MAP to Provide Access to Nilotinib, for Patients With HES","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00244686","title":"This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"GlaxoSmithKline","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}